Evidence map›Paper›PMID 40213681›Full record

ReviewFrontiers in pharmacology2025

Mechanism and therapeutic potential of liver injury induced by cholesterol-associated proteins.

Yourong Zhou, Yashi Cao, Yiming Yin, Zhifei Xu, Xiaochun Yang, Bo Yang, Peihua Luo, Hao Yan, Qiaojun He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yourong Zhou *Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Yashi Cao *Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Yiming YinCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Zhifei XuCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaochun YangCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Bo YangInstitute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Peihua LuoCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Hao YanCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Qiaojun HeCenter for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol, the most abundant sterol molecule in mammalian organisms, serves not only as a fundamental structural component of cell membranes but also as a critical regulator of cellular signaling and function. Cholesterol-associated proteins can mediate liver injury either directly by influencing cholesterol levels or through non-cholesterol pathways. These non-cholesterol pathways, which operate independently of cholesterol's traditional metabolic functions, are regulated by specific transcription factors, proteins and receptors. Dysregulation of cholesterol-associated can disrupt cellular homeostasis, leading to liver injury, metabolic disorders, and even tumorigenesis. In this article, we explore the mechanisms by which cholesterol-associated proteins contribute to liver injury via both classical cholesterol pathways and non-cholesterol pathways, and discuss their potential as therapeutic targets for liver-related diseases.

Indexed as

cholesterol metabolismcholesterol-related proteinsliver injuryregulatory factorstherapeutic targets

Identifiers

PMID40213681
PMCPMC11983413

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.